| about us | contact us | links | sitemap |
|
|
||||||||||||||
| home | forum | studies | brain games | ||||||||||||||
![]() |
||||||||||||||
|
5-HTP
|
Acetyl L-Carnitine
|
Alpha GPC |
Alpha Lipoic Acid
| Aniracetam
|
Ashwagandha | Centrophenoxine |
||||||||||||||
![]() ![]() |
Chan PL, Nutt JG, Holford NH Department of Pharmacology and
Clinical Pharmacology, University of Auckland, Auckland, New
Zealand. PURPOSE: To externally
validate the model predictions of a DATATOP cohort analysis through
application of clinical trial simulation with the study design of
the ELLDOPA trial. METHODS: The stochastic pharmacokinetic-pharmacodynamic
and disease progress model was developed from the large DATATOP
cohort of patients followed for 8 years. ELLDOPA was designed to
detect a difference between placebo and levodopa treated arms in the
total Unified Parkinson's Disease Rating Scale (UPDRS) taken at
baseline and following 2 weeks levodopa washout after 40 weeks of
treatment. The total UPDRS response was simulated with different
assumptions on levodopa effect (symptomatic with/without disease
modifying capability) and washout speed of symptomatic effect.
|
![]() ![]() |
||||||||||||
|
|
||||||||||||||